PKC inhibition results in a Kv1.5 + Kvβ1.3 pharmacology closer to Kv1.5 channels

British Journal of Pharmacology

Volumn 171, Issue 21, 2014, Pages 4914-4926

  Macias A ^a   De La Cruz, A ^a   Prieto, A ^a   Peraza, D A ^a   Tamkun, M M ^b   Gonzalez T ^a   Valenzuela, C ^a  

^a INSTITUTO DE INVESTIGACIONES BIOMÉDICAS ALBERTO SOLS   (Spain)

^b Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISINDOLYLMALEIMIDE; BISINDOLYLMALEIMIDE II; BUPIVACAINE; CALPHOSTIN C; POTASSIUM CHANNEL KV1.5; POTASSIUM CHANNEL KVBETA1.3; PROTEIN KINASE C; QUINIDINE; UNCLASSIFIED DRUG; VOLTAGE GATED POTASSIUM CHANNEL; INDOLE DERIVATIVE; KCNA5 PROTEIN, HUMAN; KCNAB1 PROTEIN, HUMAN; MALEIMIDE DERIVATIVE; NAPHTHALENE DERIVATIVE; POTASSIUM CHANNEL KV1.3;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; IC50; PHARMACOLOGICAL BLOCKING; ANTAGONISTS AND INHIBITORS; HEK293 CELL LINE; HUMAN; PHYSIOLOGY;

HEK293 CELLS; HUMANS; INDOLES; KV1.3 POTASSIUM CHANNEL; KV1.5 POTASSIUM CHANNEL; MALEIMIDES; NAPHTHALENES; PROTEIN KINASE C;

EID: 84918778441     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12822     Document Type: Article

References (45)

1. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M et al. (2013a). The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors. Br J Pharmacol 170: 1459-1581.
2. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M et al. (2013b). The Concise Guide to PHARMACOLOGY 2013/14:Ion channels. Br J Pharmacol 170: 1607-1651.
3. Alexander SPH , Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M et al. (2013c). The Concise Guide to PHARMACOLOGY 2013/14: Enzymes. Br J Pharmacol 170: 1797-1867.
4. Archer SL, Souil E, Dinh Xua n AT, Schremmer B, Mercier JC, El Yaagoubi A et al. (1998). Molecular identification of the role of voltage-gated K+ channels, Kv1.5 and Kv2.1, in hypoxic pulmonary vasoconstriction and control of resting membrane potential in rat pulmonary artery myocytes. J Clin Invest 101: 2319-2330.
5. Arias C, Guizy M, David M, Marzian S, González T, Decher N et al. (2007). KV?1.3 reduces the degree of stereoselective bupivacaine bl ock of KV1.5 channels. Anesthesiology 107: 641-651.
6. Braz JC, Bueno OF, De Windt LJ, Molkentin JD (2002). PKC alpha regulates the hypertrophic growth of cardiomyocytes through extracellular signal-regula ted kinase1/2 (ERK1/2). J Cell Biol 156: 905-919.
7. David M, Macias A, Moreno C, Prieto A, Martinez-Marmol R, Vicente R et al. (2012). PKC activity regulates functional effects of KV?1.3 on KV1.5 channels. Identification of a cardiac KV1.5 channelosome. J Biol Chem 287: 21416-21428.
8. De Biasi M, Wang Z, Accili E, Wible B, Fedida D (1997). Open channel block of human heart hKV1.5 by the beta-subunit hKVbeta1.2. Am J Physiol 272: H2932-H2941.
9. Decher N, Kumar P, Gonzalez T, Renigunta V, Sanguinetti MC (2005). Structural basis for competition between drug binding and KVbeta1.3 accessory sub unit-induced N-type inactivation of KV1.5 channels. Mol Pharmacol 68: 995-1005.
10. Fedida D, Wible B, Wang Z, Fermini B, Faust F, Nattel S et al. (1993). Identity of a novel delayed rectifier c urrent from human heart with a cloned K+ channel current. Circ Res 73: 210-216.
11. Franqueza L, Longobardo M, Vicente J, Delpon E, Tamkun MM, Tamargo J et al. (1997). Molecular determinants of stereoselective bupivacaine block of hKv1.5 channels. Circ Res 81: 1053-1064.
12. González T, Longobardo M, Caballero R, Delpon E, Tamargo J, Valenzuela C (2001). Effects of bupivacaine and a novel local anesthetic, IQB-9302, on human cardiac K+ channels. J Pharmacol Exp Ther 296: 573-583.
13. González T, Navarro-Polanco R, Arias C, Caballero R, Moreno I, Delpon E et al. (2002). Assembly w ith the Kv?1.3 subunit modulates drug block of hKv1.5 channels. Mol Pharmacol 62: 1456-1463.
14. González T, David M, Moreno C, Macias A, Valenzuela C (2010). Kv1.5-Kv beta interactions: molecular determinants and pharmacological consequences. Mini Rev Med Chem 10: 635-642.
15. Hahn HS, Marreez Y, O dley A, Sterbling A, Yussman MG, Hilty KC et al. (2003). Protein kinase Calpha negatively regulates systolic and diastolic function in pathological hypertrophy. Circ Res 93: 1111-1119.
16. Hill AP, Sunde M, Campbell TJ, Vandenberg JI (2007). Mechanism of block of the hERG K+ channel by the scorpion toxin CnErg1. Biophys J 92: 3915-3929.
17. Kerkela R, Ilves M, Pikkarainen S, Tokola H, Ronk ainen J, Vuolteenaho O et al. (2002). Identification of PKCalpha isoform-specific effects in cardiac myocytes using antisense phosphorothioate oligonucleotides. Mol Pharmacol 62: 1482-1491.
18. Kuhlkamp V,Schirdewan A,Stangl K,Homberg M,Ploch M,Beck OA 2000 Use of metoprolol CR/XL to maintain sinus rhythm after conversion from persistent atrial fibrillation: a randomized, double-blind, placebo-controlled study J Am Col l Cardiol 36 139-146.
19. Kwak YG, Hu N, Wei J, George AL Jr., Grobaski TD, Tamkun MM et al. (1999a ). Protein kinase A phosphorylation alters Kv?1.3 subunit-mediated inactivation of the Kv1.5 potassiu m channel. J Biol Chem 274: 13928-13932.
20. Kwak YG, Navarro-Polanco R, Grobaski T, Gallagher DJ, Tamkun MM (1999b ). Phosphorylation is required for alteration of Kv1.5 K+ channel function by the Kv?1.3 subunit. J Biol Chem 274: 25355-25361.
21. Li GR, Feng J, Wang Z, Fermini B, Nattel S (1996). Adrenergic modulation of ultrarapid delayed rectifier K+ current in human atrial myocytes. Circ Res 78: 903-915.
22. Longobardo M, Delpon E, Caballero R, Tamargo J, Valenzuela C (1998). Structural determinants of potency and stereoselective block of hKv1.5 channels induced by local anesthetics. Mol Pha rmacol 54: 162-169.
23. Longobardo M, González T, Navarro-Polanco R, Caballero R, Delpon E, Tamargo J et al. (2000). Effects of a quaternary bupivacaine derivative on delayed rectifier K+ currents. Br J Pharmacol 130: 391-401.
24. Longobardo M, González T, Caballero R, Delpon E, Tamargo J, Valenzuela C (2001). Bupivacaine effects on hKv1.5 channels are dependent on extracellular pH. Br J Pharmacol 134: 359-369.
25. Murray KT, Fahrig SA, Deal KK, Po SS, Hu NN, Snyders DJ et al. (1994). Modulation of an inactivating human cardiac K+ channel by protein kinase C. Circ Res 75: 999-1005.
26. Olson TM, Alekseev AE, Liu XK, Park S, Zingman LV, Bienengraeber M et al. (2006). Kv1.5 channelopathy due to KCNA5 loss-of-function mutation causes human atrial fibrillation. Hum Mol Gene t 15: 2185-2191.
27. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, Davenport AP, McGrath JC, Peters JA, Southan C, Spedding M, Yu W, Harmar AJ; NC-IUPHAR.(2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands. Nucl. Acids Res 42 (Database Issue): D1098-106.
28. Piao L, Fang YH, Parikh KS, Ryan JJ, D'Souza KM, Theccanat T et al. (2012). GRK2-mediated inhibition of adrenergic and dopaminergic signaling in right ventricular hypertrophy: therapeutic implications in pulmonary hype rtension. Circulation 126: 2859-2869.
29. Ravens U, Wettwer E (2011). Ultra-rapid delayed rectifier channels: molecular basis and therapeutic implications. Cardiovasc Res 89: 776-785.
30. R emillard CV, Tigno DD, Platoshyn O, Burg ED, Brevnova EE, Conger D et al. (2007). Function of Kv1.5 channels and genetic variations of KCNA5 in patients with idiopathic pulmonary arterial hypertension. Am J Physiol Ce ll Physiol 292: C1837-C1853.
31. Sabbah HN (2004). Biologic rationale for the use of beta-blockers in the treatment of heart failure. Heart Fail Rev 9: 91-97.
32. Schlaich MP, Kaye DM, La mbert E, Sommerville M, Socratous F, Esler MD (2003). Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation 108: 560-565.
33. Schlaich MP, Kaye DM, Lambert E, Hastings J, Campbell DJ, Lambert G et al. (2005). Angiotensin II and norepinephrine release: interaction and effects on the heart. J Hypertens 23: 1077-1082.
34. Snyders DJ, Knoth KM, Roberds SL, Tamkun MM (1992). Time-, voltage-, and state-dependent block by quinidine of a cloned human cardiac potassium channel. Mol Pharmacol 41: 322-330.
35. Snyders DJ, Tamkun MM, Bennett PB (199 3). A rapidly activating and slowly inactivating potassium channel cloned from human heart. Functional analysis after stable mammalian cell culture expression. J Gen Physiol 101: 513-543.
36. Takeishi Y, Jalili T, Ball NA, Walsh RA (1999). Responses of cardiac protein kinase C isoforms to distinct pathological stimuli are differentially regulated. Circ Res 85: 264-271.
37. Uebele VN, England SK, Chaudhary A, Tamk un MM, Snyders DJ (1996). Functional differences in Kv1.5 currents expressed in mammalian cell lines are due to the presence of endogenous Kv?2.1 subunits. J Biol Chem 271: 2406-2412.
38. Uebele VN, England SK, Gallagher DJ, Snyders DJ, Bennett PB, Tamkun MM (1998). Distinct domains of the voltage-gated K+ channel Kv?1.3 ?-subunit affect voltage-dependent gating. Am J Physiol 274: C1485-C1495.
39. Valenzuela C (2003). Pharmacological electrical remodelling in human atria induced by chronic beta-blockade. Cardiovasc Res 58: 498-500.
40. Valenzuela C, Delpon E, Tamkun MM, Tamargo J, Snyders DJ (1995). Stereoselective block of a human cardiac potassium channel (Kv1.5) by bupivacaine enantiomers. Biophys J 69: 418-427.
41. Williams CP, Hu N, Shen W, Mashburn AB, Murray KT (2002). Modulation of the human Kv1.5 channel by protein kinase C activation: role of the Kvbeta1.2 subunit. J Pharmacol Exp Ther 302: 545-550.
42. Yeola SW, Rich TC, Uebele VN, Tamkun MM, Snyders DJ (1996). Molecular analysis of a binding site for quinidine in a human cardiac delayed rectifier K+ channel. Role of S6 in antiarrhythmic drug binding. Circ Res 78: 1105-1114.
43. Yuan JX, Aldinger AM, Juhaszova M, Wang J, Conte JV Jr., Gaine SP et al. (1998). Dysfunctional voltage-gated K+ channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension. Circulation 98: 1400-1406.
44. Zagotta WN, Hoshi T, Aldrich RW (1989). Gating of single Shaker potassium channels in Drosophila muscle and in Xenopus oocytes injected with Shaker mRNA. Proc Natl Acad Sci U S A 86: 7243-7247.
45. Zhang X, Szeto C, Gao E, Tang M, Jin J, Fu Q et al. (2013). Cardiotoxic and cardioprotective features of chronic beta-Adrenergic signaling. Circ Res 112: 498-509.